Plain-English translation of NCT04679012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new medication, combined with standard chemotherapy drugs to treat Richter's transformation—a serious condition where chronic lymphocytic leukemia suddenly becomes an aggressive lymphoma. Researchers want to see if adding this medication to chemotherapy helps people with this aggressive form live longer and feel better. About 20 patients will receive the medication as inpatient treatment over several cycles.
Richter's transformation is a rare and serious development in chronic lymphocytic leukemia that is very hard to treat with current options. This trial is testing whether the new medication can work better when combined with existing chemotherapy to help patients fight this aggressive cancer.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital as an inpatient to receive treatment. You'll get the new medication () on the first day of each treatment cycle, along with the standard chemotherapy drugs. Treatment cycles repeat every 21 days for a total of 6 cycles. During your stay, you'll have blood tests and monitoring to check how you're responding and watch for any side effects. The study team will follow how well the medication works and track your health throughout the treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States